{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:42:57Z","timestamp":1790678577270,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejca.2017.02.028","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T23:22:22Z","timestamp":1490916142000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A\u00a0systematic review and a meta-analysis"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-2966","authenticated-orcid":false,"given":"Leonardo","family":"Campiotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9139-7538","authenticated-orcid":false,"given":"Matteo Basilio","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4198-9620","authenticated-orcid":false,"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.02.028_bib1","series-title":"Chronic myelogenous leukemia","author":"National Comprehensive Cancer Network","year":"2015"},{"key":"10.1016\/j.ejca.2017.02.028_bib2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.028_bib3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.028_bib4","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.02.028_bib5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.028_bib6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.028_bib7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","article-title":"Quality of life outcome in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison","volume":"21","author":"Phillips","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2017.02.028_bib8","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ejca.2017.02.028_bib9","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","article-title":"Price of drugs for chronic myeloid leukemia (CML), reflections on the unsustainable cancer drug prices: perspective of CML experts","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.028_bib10","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1007\/s00277-015-2320-4","article-title":"Discontinuation of tyrosine kinase therapy in CML","volume":"94","author":"Mahon","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2017.02.028_bib11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2017.02.028_bib12","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2017.02.028_bib13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/bmj.316.7125.129","article-title":"Statistics notes. Weighted comparison of means","volume":"316","author":"Bland","year":"1998","journal-title":"Br Med J"},{"key":"10.1016\/j.ejca.2017.02.028_bib14","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.02.028_bib15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.ejca.2017.02.028_bib16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"Br Med J"},{"key":"10.1016\/j.ejca.2017.02.028_bib17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.028_bib18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/ejh.12258","article-title":"Imatinib and pegylated IFN-\u03b12b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response","volume":"92","author":"Koskenvesa","year":"2014","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.ejca.2017.02.028_bib19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2017.02.028_bib20","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.831092","article-title":"Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience","volume":"55","author":"Benjamini","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"10.1016\/j.ejca.2017.02.028_bib21","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.028_bib22","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2017.02.028_bib23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2017.02.028_bib24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cyto.2011.11.018","article-title":"Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia","volume":"57","author":"Hardan","year":"2012","journal-title":"Cytokine"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.028_bib25","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejca.2017.02.028_bib26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.02.028_bib27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","article-title":"Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front line imatinib mesylate therapy and achieved complete molecular response","volume":"36","author":"Yhim","year":"2012","journal-title":"Leuk Res"},{"issue":"9","key":"10.1016\/j.ejca.2017.02.028_bib28","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood-2012-02-408229","article-title":"Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response","volume":"120","author":"Legros","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2017.02.028_bib29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","article-title":"Long term results of high dose imatinib in children and adolescence with chronic myeloid leukaemia in chronic phase: the Italian experience","volume":"170","author":"Giona","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.02.028_bib30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.028_bib31","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV trial","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.ejca.2017.02.028_bib32","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.02.028_bib33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.02.028_bib34","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3324\/haematol.2012.062844","article-title":"Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials","volume":"97","author":"Tang","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2017.02.028_bib35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.hoc.2011.09.001","article-title":"Hurdles toward a cure for CML: the CML stem cell","volume":"25","author":"Gallipoli","year":"2011","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ejca.2017.02.028_bib36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11899-012-0117-2","article-title":"Curing chronic myeloid leukemia","volume":"7","author":"Rea","year":"2012","journal-title":"Curr Hematol Malignancy Rep"},{"key":"10.1016\/j.ejca.2017.02.028_bib37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/187152010790909326","article-title":"Novel therapeutic agents against cancer stem cell of chronic myeloid leukemia","volume":"10","author":"Chen","year":"2011","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.ejca.2017.02.028_bib38","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1365-2141.2000.02366.x","article-title":"Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia","volume":"111","author":"Bonifazi","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.02.028_bib39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2017.02.028_bib40","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","volume":"27","author":"Hoffmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2017.02.028_bib41","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2017.02.028_bib42","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2017.02.028_bib43","unstructured":"Treatment-free remission accomplished with dasatinib in patients with CML (TRAD), NCT02268370. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02268370."},{"key":"10.1016\/j.ejca.2017.02.028_bib44","unstructured":"Nilotinib treatment-free remission study in CML patients (ENESTFreedom ), NCT01784068. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01784068."},{"key":"10.1016\/j.ejca.2017.02.028_bib45","unstructured":"Treatment-free remission after sustained MR4.5 on nilotinib (ENESTop), NCT01698905. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01698905."},{"key":"10.1016\/j.ejca.2017.02.028_bib46","unstructured":"Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing nilotinib versus imatinib with switch to nilotinib in absence of optimal response. NCT02602314. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02602314."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917307943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T23:53:47Z","timestamp":1535932427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917307943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":46,"alternative-id":["S0959804917307943"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A\u00a0systematic review and a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}